Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Callegari, Elisa ^a   Elamin, Bahaeldin K ^a,b   D'Abundo, Lucilla ^a   Falzoni, Simonetta ^a   Donvito, Giovanna ^a   Moshiri, Farzaneh ^a,f   Milazzo, Maddalena ^c   Altavilla, Giuseppe ^d   Giacomelli, Luciano ^d   Fornari, Francesca ^c   Hemminki, Akseli ^e   Di Virgilio, Francesco ^a   Gramantieri, Laura ^c   Negrini, Massimo ^a   Sabbioni, Silvia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF HELSINKI   (Finland)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 199; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 199T; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; TUMOR XENOGRAFT; VIRUS EXPRESSION; VIRUS REPLICATION;

3' UNTRANSLATED REGIONS; ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; GENE ORDER; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA INTERFERENCE; TUMOR BURDEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884189820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073964     Document Type: Article

References (54)

1. Mathis JM, Stoff-Khalili MA, Curiel DT, (2005) Oncolytic adenoviruses- selective retargeting to tumor cells. Oncogene 24: 7775-7791. doi:10.1038/sj.onc.1209044. PubMed: 16299537.
2. Alemany R, (2007) Cancer selective adenoviruses. Mol Aspects Med 28: 42-58. doi:10.1016/j.mam.2006.12.002. PubMed: 17300834.
3. Relph K, Harrington KJ, Melcher A, Pandha HS, (2008) Adenoviruses. In: Harrington KJ, Vile RG, Pandha HS, eds. Viral Therapy of Cancer. Chichester, England: John Wiley & Sons, Ltd. pp. pp. 1-17.
4. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376. doi:10.1126/science.274.5286.373. PubMed: 8832876.
5. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, et al. (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10: 285-292. doi:10.1158/1078-0432.CCR-1075-3. PubMed: 14734481.
6. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR, (1999) The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59: 4200-4203. PubMed: 10485454.
7. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, et al. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563. PubMed: 9205053.
8. Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R, (2007) An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 67: 11309-11316. doi:10.1158/0008-5472.CAN-07-0739. PubMed: 18056457.
9. Ylösmäki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, et al. (2008) Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 82: 11009-11015. doi:10.1128/JVI.01608-08. PubMed: 18799589.
10. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355. doi:10.1038/nature02871. PubMed: 15372042.
11. Negrini M, Ferracin M, Sabbioni S, Croce CM, (2007) MicroRNAs in human cancer: from research to therapy. J Cell Sci 120: 1833-1840. doi:10.1242/jcs.03450. PubMed: 17515481.
12. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545. doi:10.1038/sj.onc.1209283. PubMed: 16331254.
13. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, et al. (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70: 5184-5193. doi:10.1158/1538-7445.AM10-5184. PubMed: 20501828.
14. Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, et al. (2008) MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 283: 18158-18166. doi:10.1074/jbc.M800186200. PubMed: 18456660.
15. Jia XQ, Cheng HQ, Qian X, Bian CX, Shi ZM, et al. (2011) Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma. Cell Biochem Biophys, 62: 237-44. PubMed: 21847633.
16. Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, et al. (2010) miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 403: 120-125. doi:10.1016/j.bbrc.2010.10.130. PubMed: 21055388.
17. Parkin DM, Bray F, Ferlay J, Pisani P, (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. doi:10.1002/ijc.1440. PubMed: 11668491.
18. Forner A, Hessheimer AJ, Isabel Real M, Bruix J, (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol/Hematol 60: 89-98. doi:10.1016/j.critrevonc.2006.06.001.
19. Bismuth H, Majno PE, Adam R, (1999) Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19: 311-322. doi:10.1055/s-2007-1007120. PubMed: 10518310.
20. Llovet JM, Fuster J, Bruix J, (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440. doi:10.1002/hep.510300629. PubMed: 10573522.
21. Jonas S, Herrmann M, Rayes N, Berg T, Radke C, et al. (2001) Survival after liver transplantation for hepatocellular carcinoma in cirrhosis according to the underlying liver disease. Transplant Proc 33: 3444-3445. doi:10.1016/S0041-1345(01)02484-8. PubMed: 11750474.
22. Cormier JN, Thomas KT, Chari RS, Pinson CW, (2006) Management of hepatocellular carcinoma. J Gastrointest Surg 10: 761-780. doi:10.1016/j.gassur.2005.10.006. PubMed: 16713550.
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390. doi:10.1056/NEJMoa0708857. PubMed: 18650514.
24. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, et al. (2012) Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56: 1025-1033. doi:10.1016/j.jhep.2011.12.021. PubMed: 22473819.
25. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, et al. (2007) Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther 6: 742-751. doi:10.1158/1535-7163.MCT-06-0403. PubMed: 17308070.
26. Ranki T, Särkioja M, Hakkarainen T, von Smitten K, Kanerva A, et al. (2007) Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 121: 165-174. doi:10.1002/ijc.22627. PubMed: 17315187.
27. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, et al. (2007) Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15: 1016-1023. doi:10.1038/mt.sj.6300120. PubMed: 17375076.
28. Yu W, Fang H, (2007) Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7: 141-148. doi:10.2174/156800907780058817. PubMed: 17346105.
29. Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, et al. (2009) A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther 16: 376-382. doi:10.1038/gt.2008.179. PubMed: 19092859.
30. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, et al. (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18: 429-434. doi:10.1038/mt.2009.262. PubMed: 19935775.
31. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, et al. (2002) Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62: 5736-5742. PubMed: 12384532.
32. Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, et al. (2007) Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res 13: 7451-7458. doi:10.1158/1078-0432.CCR-07-1265. PubMed: 18094429.
33. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, et al. (2009) Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 100: 1154-1164. doi:10.1038/sj.bjc.6604969. PubMed: 19277041.
34. Post DE, Khuri FR, Simons JW, Van Meir EG, (2003) Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14: 933-946. doi:10.1089/104303403766682205. PubMed: 12869212.
35. Chen W, Wu Y, Liu W, Wang G, Wang X, et al. (2011) Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett 307: 93-103. doi:10.1016/j.canlet.2011.03.021. PubMed: 21504839.
36. Li Y, Yu DC, Chen Y, Amin P, Zhang H, et al. (2001) A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61: 6428-6436. PubMed: 11522637.
37. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, et al. (2001) A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61: 6012-6019. PubMed: 11507044.
38. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, et al. (2003) Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125: 1203-1218. doi:10.1016/S0016-5085(03)01196-X. PubMed: 14517802.
39. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806. PubMed: 10741699.
40. Opyrchal M, Aderca I, Galanis E, (2009) Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol 542: 705-717. doi:10.1007/978-1-59745-561-9_35. PubMed: 19565928.
41. Liu TC, Kirn D, (2008) Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15: 877-884. doi:10.1038/gt.2008.72. PubMed: 18418413.
42. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L, (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591. doi:10.1038/nm1398. PubMed: 16633348.
43. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, et al. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467. doi:10.1038/nbt1372. PubMed: 18026085.
44. Brown BD, Naldini L, (2009) Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 10: 578-585. doi:10.1038/nrm2754. PubMed: 19609263.
45. Kelly EJ, Russell SJ, (2009) MicroRNAs and the regulation of vector tropism. Mol Ther 17: 409-416. doi:10.1038/mt.2008.288. PubMed: 19107117.
46. Kelly EJ, Hadac EM, Greiner S, Russell SJ, (2008) Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283. doi:10.1038/nm.1776. PubMed: 18953352.
47. Fu X, Rivera A, Tao L, De Geest B, Zhang X, (2011) Construction of an Oncolytic Herpes Simplex Virus That Precisely Targets Hepatocellular Carcinoma Cells. Mol Ther, 20: 339-46. PubMed: 22146341.
48. Hou J, Lin L, Zhou W, Wang Z, Ding G, et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243. doi:10.1016/j.ccr.2011.01.001. PubMed: 21316602.
49. Hardy B, Globerson A, Danon D, (1973) Ontogenic development of the reactivity of macrophages to antigenic stimulation. Cell Immunol 9: 282-288. doi:10.1016/0008-8749(73)90079-8. PubMed: 4584789.
50. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, et al. (2009) Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLOS Pathog 5: e1000440. PubMed: 19461878.
51. Leja J, Nilsson B, Yu D, Gustafson E, Akerström G, et al. (2010) Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLOS ONE 5: e8916. doi:10.1371/journal.pone.0008916. PubMed: 20111709.
52. Cawood R, Wong SL, Di Y, Baban DF, Seymour LW, (2011) MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity. PLOS ONE 6: e16152. doi:10.1371/journal.pone.0016152. PubMed: 21264344.
53. Ylösmäki E, Lavilla-Alonso S, Jäämaa S, Vähä-Koskela M, Hällström T, et al. (2013) MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver. PLOS ONE 8: e54506. doi:10.1371/journal.pone.0054506. PubMed: 23349911.
54. Jin H, Lv S, Yang J, Wang X, Hu H, et al. (2011) Use of MicroRNA Let-7 to Control the Replication Specificity of Oncolytic Adenovirus in Hepatocellular Carcinoma Cells. PLOS ONE 6: e21307. doi:10.1371/journal.pone.0021307. PubMed: 21814544.